EUVIMEDEUVIMED entdecken
Crossref

Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial

Supriya Chopra, Prachi Mittal, Ankita Gupta, Jayant S. Goda, Venkatesh Pai, Sadhana Kannan, Santosh Menon, Kedar Deodhar, Jeevanshu Jain, Prachi Sawant, Tanmay Wairkar, Sheela Sawant und 8 weitere

JCO Oncology Advances · 2026-01 · 3 (1)

DOI: 10.1200/oa-25-00088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-01. Verfasst von Supriya Chopra und 19 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The AKT pathway is upregulated in cervical cancer. This trial aimed to investigate whether the protease AKT pathway inhibitor (nelfinavir mesylate), in addition to chemoradiation (CRT) and image-guided brachytherapy (IGBT), could improve disease-free survival (DFS). METHODS NELCER (ClinicalTrials.gov identifier: NCT03256916 ), a phase III adaptive trial, randomly assigned patients with stage III cervical cancer (International Federation of Gynecology and Obstetrics 2018) to CRT and IGBT (standard arm) or in combination with nelfinavir (test arm). Patients in the test arm received nelfinavir 1,250 mg twice a day starting 7-10 days before and during CRT. The primary end point was 3-year DFS. Secondary end points included locoregional control, overall survival, adverse events, and quality of life. Disease-specific survival (DSS) was also estimated. The study planned to randomly assign 348 patients to detect a hazard ratio (HR) of 0.66. Futility analysis was scheduled at 32 events. RESULTS Ninety-two patients were recruited at the time of futility analysis. The stage was IIIA-B (43.5%), IIIC1 (48.9%), and IIIC2 (7.6%) patients. The median prescribed dose to high-risk clinical target volume was 88 Gy 10 (IQR, 83.6-92 Gy 10 ). At a median follow-up of 34.9 months (29-40.8), the 3-year DFS was 71% (95% CI, 0.58 to 0.86) in the standard arm and 56% in the nelfinavir arm (95% CI, 0.43 to 0.70; HR, 1.34 [0.66 to 2.7]; P = .40). The nelfinavir arm had a higher incidence of acute grade ≥ 3 (8.7% v 0%, P = .04) GI effects. The 3-year DSS was 82% (95% CI, 0.70 to 0.95) in the standard arm and 57% (95% CI, 0.43 to 0.75) in the nelfinavir arm (HR of 1.97 [0.87 to 4.4], P = .09). The z-value was 0.74. CONCLUSION The 3-year DFS did not cross prespecified statistical boundary; however, on the basis of DSS and acute adverse events, nelfinavir was not considered clinically efficacious, and the trial was stopped at the first interim analysis.

Zitieren

APA

Chopra, S., Mittal, P., Gupta, A., Goda, J. S., Pai, V., Kannan, S., Menon, S., Deodhar, K., Jain, J., Sawant, P., Wairkar, T., Sawant, S., Thakkar, P., Nookala, M., Ghosh, J., Rath, S., Popat, P., Rangarajan, V., Gota, V., & Gupta, S. (2026). Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial. JCO Oncology Advances, 3(1). https://doi.org/10.1200/oa-25-00088

Vancouver

Chopra S, Mittal P, Gupta A, Goda JS, Pai V, Kannan S, et al. Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial. JCO Oncology Advances. 2026;3(1). doi:10.1200/oa-25-00088

BibTeX
@article{Chopra2026,
  author = {Chopra, Supriya and Mittal, Prachi and Gupta, Ankita and Goda, Jayant S. and Pai, Venkatesh and Kannan, Sadhana and Menon, Santosh and Deodhar, Kedar and Jain, Jeevanshu and Sawant, Prachi and Wairkar, Tanmay and Sawant, Sheela and Thakkar, Prafulla and Nookala, Manjunath and Ghosh, Jaya and Rath, Sushmita and Popat, Palak and Rangarajan, Venkatesh and Gota, Vikram and Gupta, Sudeep},
  title = {Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.1200/oa-25-00088}
}
Kostenlos starten →